At ASH, Bluebird Disappoints (Again) While Bellicum Shines

Research - Just as investors were getting comfortable with bluebird bio’s (BLUE) most recent disappointment, it’s happened again. Today at the American Society of Hematology’s annual meeting, bluebird revealed updated results from HGB-206, the company’s small phase 1/2 study dedicated exclusively to treating Sickle Cell Disease patients with LentiGlobin.

Premium

Filling the Void in Beta Thalassemia

Research - Bellicum Pharmaceuticals (BLCM) after the bell this evening reported third quarter earnings, but more importantly noted that four pediatric beta-thalassemia patients who underwent HSCT followed by BPX-501 modified T cells are transfusion-free.

Premium